Data investigation

What 262 Trials Say Together

262 trials, 99,791 people, 19 drugs, every result graded. Three of its findings cut against how this field is described, starting with the fact that the drug with the mortality evidence is not the one that takes off the most weight.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
9 min read·3 citations

The BMJ pooled 262 randomized trials covering 99,791 people and 19 drugs, graded the certainty of every result, and produced the best available answer to which obesity drug is best.[1] Three of its findings cut against how this field is usually described. One is that the drug with the strongest evidence for keeping people alive is not the one that takes off the most weight.

Weight loss at one year

Mean difference in body weight at one year against lifestyle modification alone, moderate to high certainty.[1]
DrugWeight difference95% CI
Tirzepatide−14.9%−16.0 to −13.9
Cagrilintide–semaglutide (CagriSema)−14.8%−16.9 to −12.7
Oral semaglutide−10.9%−12.7 to −9.1
Orforglipron−9.9%−12.4 to −7.5
Subcutaneous semaglutide−9.8%−10.6 to −9.1
Phentermine–topiramate−8.1%−9.7 to −6.5
If that subcutaneous semaglutide figure looks wrong, it is measuring something different from the number you are thinking of. The famous 14.9% is the average loss on the drug in a single placebo-controlled trial.[2] This is a pooled estimate against lifestyle modification, across every eligible trial and dose, over a standardized one-year horizon. Both are correct answers to different questions, and only one of them lets you line nineteen drugs up beside each other.

The newer agents (ecnoglutide, mazdutide, retatrutide) may reach 13.1% to 14.6%, but at very low to low certainty, which is the analysis’s way of saying the evidence is thin enough that these numbers could move substantially. Carry that grading into any conversation about drugs you cannot yet be prescribed.

The drug with the outcome evidence is not the strongest one

Weight is a proxy. What people want is to live longer and avoid heart attacks. On those outcomes the ranking reorders completely.

Hard outcomes. Only agents with a credible signal are listed.[1]
OutcomeDrugRisk ratio (95% CI)
All-cause mortalitySubcutaneous semaglutide only0.81 (0.72–0.93)
Myocardial infarctionSubcutaneous semaglutide only0.72 (0.61–0.85)
Heart failureSubcutaneous semaglutide0.43 (0.21–0.84)
Heart failureTirzepatide0.49 (0.27–0.88)
Kidney failureNone convincingly—
The only drug associated with fewer deaths is fifth on the weight-loss table.
One caveat has to travel with those two rows. The mortality and heart attack estimates are largely informed by cardiovascular outcome trials conducted in people who were already at high risk. They describe what the drug does for someone with established cardiovascular disease. They do not establish that a healthy person taking it for weight will live longer.

The reason the ranking reorders is not mysterious: the drug that has been studied longest in the sickest people has the outcome data. Tirzepatide may well show the same or better in time. Right now it has not, and “loses more weight” and “prevents more deaths” are separate claims requiring separate evidence.

No drug cleared the quality-of-life threshold

Across 43 trials and 45,663 participants, no drug improved quality of life beyond the established threshold for a difference patients notice. Every mean difference came in under 5 points on scales where 10 is the minimally important difference.

That is a pooled average, and single questionnaires can read higher. A 2026 analysis of six tirzepatide trials found physical function 10.10 points better than placebo on the weight-specific IWQOL-Lite-CT, but only 2.26 points better on the general SF-36, with results so inconsistent between trials that its authors urged caution.[4] In SURMOUNT-4, people who stayed on tirzepatide finished 11.1 points ahead of those switched to placebo on the IWQOL-Lite-CT total score.[5] That trial measures what is lost on stopping, in people who had already tolerated the drug. These are different scales and designs, so they qualify the review without overturning it.

That is a striking result for treatments whose entire promise is feeling better, and it independently confirms something we reported from the head-to-head trial, where the mental component of a quality-of-life survey did not significantly improve in either arm over 72 weeks (see the mental health score that did not move). One trial finding that is easy to dismiss. Forty-three trials finding it is not.

It does not mean nobody feels better. It means that across the assembled evidence, the average improvement on validated instruments falls below what researchers had agreed in advance would count as noticeable. It is also a claim about general instruments. In heart failure, where a disease-specific symptom score was used, both drugs tested produced improvements patients would notice (see the one place people felt better).

Bigger effects, bigger costs

The analysis’s own conclusion is that larger benefits are generally accompanied by greater harms and more discontinuation. The specifics bear that out.

  • Stopping because of side effects was highest with orforglipron, naltrexone–bupropion and liraglutide, as well as phentermine–topiramate, CagriSema and oral semaglutide (risk ratios 1.9 to 4.2).
  • Gastrointestinal events were most increased with naltrexone–bupropion, oral semaglutide, orforglipron and tirzepatide (risk ratios 3.1 to 4.2).
  • Fatigue rose with naltrexone–bupropion (risk ratio 8.9, an extra 331 people per 1,000 over a year), orforglipron (3.4, 100 more per 1,000) and CagriSema (3.2, 92 more per 1,000). Treat the first figure with caution: the Contrave label, pooling its placebo-controlled trials, lists fatigue in 4.0% on the drug and 3.4% on placebo, and the review’s abstract does not explain the gap.[3]
  • Tirzepatide cut fat mass by the largest margin (25.7%), and lean mass by the largest margin too (8.3%).

Two of those deserve a second look. Orforglipron appears on both the discontinuation and gastrointestinal lists. That matches its own head-to-head trial against oral semaglutide, which found roughly double the dropouts (see the first pill-versus-pill trial). And the tirzepatide body composition row is the muscle question quantified: the drug that removes the most fat also removes the most lean tissue, which is what lean mass on a drug versus dieting examines.

What the subgroups did not show

One quiet finding is useful because it is negative. Subgroup analyses across drug dosages and patient characteristics did not identify credible differences in relative treatment effects. The one exception was that longer trials showed larger weight reductions for subcutaneous semaglutide.

In plain terms, nothing in the evidence suggests that particular kinds of patient respond differently in a way anyone can currently predict. That is the same conclusion reached from a different direction by the genetics work, where real predictors exist and are too small to act on (see the genetics are real, and small).

Frequently Asked Questions

Tirzepatide, at 14.9% below lifestyle modification alone at one year, closely followed by cagrilintide-semaglutide at 14.8%. Both estimates carry moderate to high certainty in the 262-trial analysis.
Because this is a pooled estimate against lifestyle modification, across all eligible trials and doses over a standardized year. The familiar 14.9% is the average loss on the drug in one placebo-controlled trial. Both are correct answers to different questions.
Subcutaneous semaglutide, and only it, with a risk ratio of 0.81 for all-cause mortality and 0.72 for myocardial infarction. Those estimates come largely from trials in people already at high cardiovascular risk, so they do not establish the same benefit for a healthy person taking it for weight.
Across 43 trials and 45,663 participants, no drug improved quality of life beyond the threshold agreed in advance as noticeable to patients. Every mean difference was under 5 points where 10 is the minimally important difference. Weight-specific questionnaires in tirzepatide trials have shown larger differences, of about 10 points, on a different scale.
Discontinuation for adverse events was highest with orforglipron, naltrexone-bupropion and liraglutide, as well as phentermine-topiramate, CagriSema and oral semaglutide. Fatigue rose most with naltrexone-bupropion in this analysis, at an extra 331 people per 1,000 over a year, though the Contrave label's pooled trials list fatigue at only 4.0% on the drug against 3.4% on placebo.
Tirzepatide cut fat mass by the largest margin, 25.7%, and lean mass by the largest margin too, 8.3%.

References

  1. 1.Nong K, Shi Q, Xie X, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis BMJ. 2026. PMID: 42419792.
  2. 2.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity N Engl J Med. 2021. PMID: 33567185.
  3. 3.Nalpropion Pharmaceuticals CONTRAVE (naltrexone and bupropion) extended-release tablets: prescribing information (section 6.1) DailyMed, U.S. National Library of Medicine. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b
  4. 4.Schmidt PHS, de Souza VSN, Machado LG, et al. Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis Diabetes Obes Metab. 2026. PMID: 41705736.
  5. 5.Gibble TH, Cao D, Murphy M, et al. Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4 Obesity (Silver Spring). 2025. PMID: 40903801.

The Head-to-Head, and What It Settles

751 adults randomized to tirzepatide or semaglutide, each at maximum tolerated dose, for 72 weeks. Tirzepatide produced 20.2% weight loss against 13.7%, and on several other endpoints the answer runs the other way.

7 min read

The Drugs Nobody Writes About

A pharmacovigilance study found muscle atrophy reported disproportionately with semaglutide and tirzepatide. The same table shows two older drugs of the same class reported significantly less often than average.

6 min read

The Diet Advice Nobody Has Tested

Everyone on these drugs is told to hit a protein target, drink more, add fiber. A review of 16 randomized trials of these drugs given alongside dietary guidance concluded that evidence on the optimal nutritional approach remains limited.

7 min read

Does Weight Loss Fake Kidney Numbers?

Estimated kidney function is calculated from creatinine, and creatinine comes from muscle, so weight loss could flatter the number. A trial checked the estimates against a directly measured filtration rate.

7 min read

Newer Is Not Stronger

Survodutide has a new mechanism and phase 3 results in the NEJM. It produced 13.0% weight loss at 76 weeks, and its higher dose caused gut side effects in nearly nine of ten participants while losing only 0.8 points more weight than the lower dose.

7 min read

What Tripling the Dose Buys

A higher semaglutide dose produced 18.7% weight loss against 15.6% on the standard dose. Three extra percentage points is the benefit; the costs are in the safety table.

7 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.5

Gala

Moving between compounded and brand without changing seller

9.3

Embody

A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →